Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614993 | 0.94 | CNR1 (1.00) | CNR1 | |
| SCHEMBL3090745 | 0.92 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL4247667 | 0.86 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL4905683 | 0.86 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4615190 | 0.86 | CNR1 (1.00) | CNR1 | |
| SCHEMBL3089489 | 0.85 | CNR1 (0.73) | CNR1CNR2 | |
| SCHEMBL4617873 | 0.85 | CNR1 (1.00) | CNR1 | |
| SCHEMBL3089255 | 0.84 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL4896171 | 0.84 | CNR1 (0.75) | CNR1 | |
| SCHEMBL4615029 | 0.83 | CNR1 (0.81) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| EP-1940803-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | claimed |
| US-20070208059-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2007-09-06 | — | — | US | claimed |
| WO-2007031720-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | claimed |
| US-7799804-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1940803-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070208059-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007031720-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885 |
| US-20070208059-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | CNR1 193/4885CNR2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.